WO2024030956A3 - Cd39-specific binding agents and methods of using the same - Google Patents

Cd39-specific binding agents and methods of using the same Download PDF

Info

Publication number
WO2024030956A3
WO2024030956A3 PCT/US2023/071512 US2023071512W WO2024030956A3 WO 2024030956 A3 WO2024030956 A3 WO 2024030956A3 US 2023071512 W US2023071512 W US 2023071512W WO 2024030956 A3 WO2024030956 A3 WO 2024030956A3
Authority
WO
WIPO (PCT)
Prior art keywords
binding agents
methods
same
specific binding
antibodies
Prior art date
Application number
PCT/US2023/071512
Other languages
French (fr)
Other versions
WO2024030956A2 (en
Inventor
Courtney Crane
Susan JULIEN
Su Jung YANG
Kristine SWIDEREK
Original Assignee
Mozart Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mozart Therapeutics, Inc. filed Critical Mozart Therapeutics, Inc.
Publication of WO2024030956A2 publication Critical patent/WO2024030956A2/en
Publication of WO2024030956A3 publication Critical patent/WO2024030956A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Binding agents (e.g., antibodies or antibody binding fragments thereof) that specifically bind to CD39 expressed on CD8+ T regulatory cells, and their use in the treatment of diseases or disorders, such as an inflammatory disease or an autoimmune disease, are provided.
PCT/US2023/071512 2022-08-03 2023-08-02 Cd39-specific binding agents and methods of using the same WO2024030956A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263370353P 2022-08-03 2022-08-03
US63/370,353 2022-08-03
US202263380879P 2022-10-25 2022-10-25
US63/380,879 2022-10-25

Publications (2)

Publication Number Publication Date
WO2024030956A2 WO2024030956A2 (en) 2024-02-08
WO2024030956A3 true WO2024030956A3 (en) 2024-04-11

Family

ID=87800863

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/071512 WO2024030956A2 (en) 2022-08-03 2023-08-02 Cd39-specific binding agents and methods of using the same

Country Status (1)

Country Link
WO (1) WO2024030956A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2737907A2 (en) * 2007-05-07 2014-06-04 MedImmune, LLC Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
WO2016120789A1 (en) * 2015-01-28 2016-08-04 Glaxosmithkline Intellectual Property Development Limited Agonistic icos binding proteins
WO2019027935A1 (en) * 2017-07-31 2019-02-07 Tizona Therapeutics Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
WO2021037037A1 (en) * 2019-08-27 2021-03-04 Elpiscience (Suzhou) Biopharma, Ltd. Novel anti-cd39 antibodies
WO2021209356A1 (en) * 2020-04-14 2021-10-21 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
JPS63501765A (en) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド Antibody gene module assembly, antibodies produced thereby, and uses
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE69233254T2 (en) 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanized Heregulin antibody
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US6080560A (en) 1994-07-25 2000-06-27 Monsanto Company Method for producing antibodies in plant cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
DE19742706B4 (en) 1997-09-26 2013-07-25 Pieris Proteolab Ag lipocalin muteins
EP1068241B1 (en) 1998-04-02 2007-10-10 Genentech, Inc. Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US20030167531A1 (en) 1998-07-10 2003-09-04 Russell Douglas A. Expression and purification of bioactive, authentic polypeptides from plants
US6512162B2 (en) 1998-07-10 2003-01-28 Calgene Llc Expression of eukaryotic peptides in plant plastids
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
BR0014945A (en) 1999-10-21 2004-08-31 Monsanto Co Posttranslational modification of recombinant proteins produced in plants
NZ521540A (en) 2000-04-11 2004-09-24 Genentech Inc Multivalent antibodies and uses therefor
JP5291279B2 (en) 2000-09-08 2013-09-18 ウニヴェルジテート・チューリッヒ A collection of repetitive proteins containing repetitive modules
HU227217B1 (en) 2002-12-16 2010-11-29 Genentech Inc Immunoglobulin variants and uses thereof
AU2004242846A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
AU2003275958A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of tear lipocalin
AU2004283299B2 (en) 2003-10-22 2009-06-18 Alder Biopharmaceuticals, Inc. Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy
SI1691833T1 (en) 2003-11-28 2010-06-30 Micromet Ag Compositions comprising polypeptides
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
NZ549872A (en) 2004-04-13 2009-09-25 Hoffmann La Roche Anti-P-selectin antibodies
TWI380996B (en) 2004-09-17 2013-01-01 Hoffmann La Roche Anti-ox40l antibodies
NZ612578A (en) 2005-08-19 2014-11-28 Abbvie Inc Dual variable domain immunoglobin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
ES2616316T3 (en) 2005-10-11 2017-06-12 Amgen Research (Munich) Gmbh Compositions comprising specific antibodies for different species and uses thereof
WO2008027236A2 (en) 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
WO2008119567A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
EP2235064B1 (en) 2008-01-07 2015-11-25 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
EP2238170B1 (en) 2008-01-31 2016-11-23 INSERM - Institut National de la Santé et de la Recherche Médicale Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity
DK2654789T3 (en) 2010-12-22 2018-09-03 Orega Biotech ANTIBODIES AGAINST HUMAN CD39 AND USE THEREOF
PT2691417T (en) 2011-03-29 2018-10-31 Roche Glycart Ag Antibody fc variants
ES2659764T3 (en) 2011-08-23 2018-03-19 Roche Glycart Ag Bispecific T-cell activating antigen binding molecules
PL3430397T3 (en) 2016-03-14 2022-04-04 Biogen International Neuroscience Gmbh Antibody-dependent cell-mediated phagocytosis assay for reliably measuring uptake of aggregated proteins
AU2018314257A1 (en) 2017-08-11 2020-02-13 Research Development Foundation Engineered antibody Fc variants for enhanced serum half life

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2737907A2 (en) * 2007-05-07 2014-06-04 MedImmune, LLC Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
WO2016120789A1 (en) * 2015-01-28 2016-08-04 Glaxosmithkline Intellectual Property Development Limited Agonistic icos binding proteins
WO2019027935A1 (en) * 2017-07-31 2019-02-07 Tizona Therapeutics Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
WO2021037037A1 (en) * 2019-08-27 2021-03-04 Elpiscience (Suzhou) Biopharma, Ltd. Novel anti-cd39 antibodies
WO2021209356A1 (en) * 2020-04-14 2021-10-21 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CINZIA SOLINAS ET AL: "The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy", ESMO OPEN, vol. 5, no. 1, 1 January 2020 (2020-01-01), pages e000544, XP055735963, DOI: 10.1136/esmoopen-2019-000544 *
HU DAN ET AL: "CD8+ Tregs kill pathogenic cells to avert autoimmunity", TRENDS IN IMMUNOLOGY, vol. 43, no. 6, 1 June 2022 (2022-06-01), GB, pages 415 - 416, XP093112296, ISSN: 1471-4906, Retrieved from the Internet <URL:https://www.cell.com/trends/immunology/pdf/S1471-4906(22)00092-8.pdf> DOI: 10.1016/j.it.2022.04.006 *
IVAN PERROT ET AL: "Blocking Antibodies Targeting the CD39/CD73 Immunosuppressive Pathway Unleash Immune Responses in Combination Cancer Therapies", CELL REPORTS, vol. 27, no. 8, 1 May 2019 (2019-05-01), US, pages 2411 - 2425.e9, XP055610275, ISSN: 2211-1247, DOI: 10.1016/j.celrep.2019.04.091 *
LI JING ET AL: "KIR + CD8 + T cells suppress pathogenic T cells and are active in autoimmune diseases and COVID-19", SCIENCE, vol. 376, no. 6590, 15 April 2022 (2022-04-15), US, XP093112109, ISSN: 0036-8075, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8995031/pdf/science.abi9591.pdf> DOI: 10.1126/science.abi9591 *
SIMPSON TYLER R ET AL: "Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS)", CURRENT OPINION IN IMMUNOLOGY, vol. 22, no. 3, 1 June 2010 (2010-06-01), GB, pages 326 - 332, XP093112300, ISSN: 0952-7915, Retrieved from the Internet <URL:https://pdf.sciencedirectassets.com/272032/1-s2.0-S0952791510X00048/1-s2.0-S0952791510000026/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjEOX//////////wEaCXVzLWVhc3QtMSJHMEUCIEcy1LN4tWYuGxXwwgfynwykhNLiYCb3VIRO+NYA1xHcAiEAoSl96oP6sTHWLTpkRYR9tFfvr0xDv1jn1hny2PXfF0cqsgUIXhAFGgwwNTkwMDM1NDY4NjUiDI0Q7> DOI: 10.1016/j.coi.2010.01.001 *
TIMPERI ELEONORA ET AL: "CD39 Regulation and Functions in T Cells", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 22, no. 15, 28 July 2021 (2021-07-28), Basel, CH, pages 8068, XP093112249, ISSN: 1422-0067, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8348030/pdf/ijms-22-08068.pdf> DOI: 10.3390/ijms22158068 *
VIEYRA-LOBATO MARTHA R. ET AL: "Description of CD8 + Regulatory T Lymphocytes and Their Specific Intervention in Graft-versus-Host and Infectious Diseases, Autoimmunity, and Cancer", JOURNAL OF IMMUNOLOGY RESEARCH, vol. 2018, 5 August 2018 (2018-08-05), US, pages 1 - 16, XP093112250, ISSN: 2314-8861, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6098849/pdf/JIR2018-3758713.pdf> DOI: 10.1155/2018/3758713 *
ZHANG ZHENQING ET AL.: "Abstract 5528: A highly potent anti-CD39 biparatopic antibody and bispecific for cancer therapy | Cancer Research | American Association for Cancer Research", CANCER RESEARCH, 15 June 2022 (2022-06-15), XP093108860, Retrieved from the Internet <URL:https://aacrjournals.org/cancerres/article/82/12_Supplement/5528/700582/Abstract-5528-A-highly-potent-anti-CD39> *

Also Published As

Publication number Publication date
WO2024030956A2 (en) 2024-02-08

Similar Documents

Publication Publication Date Title
EP1603949B8 (en) Antibodies against human il-21 receptor and uses therefor
MY146664A (en) Antibodies against human il-22 and uses therefor
WO2007100643A3 (en) Methods of using antibodies against human il-22
WO2019178269A3 (en) Antibodies that bind cd39 and uses thereof
IL173477A (en) Multispecific antibody comprising binding arms which bind to two different antigens on the same target cell and its use in the preparation of a pharmaceutical composition
WO2006077471A3 (en) Combining therapies targeting multiple toll-like receptors and use thereof
NO20073063L (en) Monoclonal antibody to NKG2A
WO2007126439A3 (en) Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
WO2005110474A3 (en) HUMANIZED FcϜRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
MX2010003574A (en) Il-23 antibodies.
AU2018282094A1 (en) Antibodies that specifically bind PD-1 and methods of use
WO2006003179A3 (en) Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use
WO2007084775A3 (en) Compositions and methods for modulation of suppressor t cell activation
WO2011094259A3 (en) Cd127 binding proteins
WO2021055253A3 (en) Anti-tnfr2 antibodies and methods of use
WO2005120557A3 (en) Inhibition of macrophage-stimulating protein receptor (ron)
WO2022081718A8 (en) Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
WO2016173605A8 (en) Ultra-potent neutralization of cytokines by multispecific antibodies and uses thereof
WO2020089396A3 (en) Composition and methods of treating inflammatory and autoimmune diseases
MX2021011040A (en) Antibodies targeting c5ar.
WO2021263167A3 (en) Il-10 muteins and fusion proteins thereof
MY149448A (en) Interleukin-21 receptor binding proteins
WO2021087368A3 (en) Anti-cd45 antibodies and conjugates thereof
WO2024030956A3 (en) Cd39-specific binding agents and methods of using the same
WO2020185796A9 (en) High avidity wt1 t cell receptors and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23761376

Country of ref document: EP

Kind code of ref document: A2